- Home
- NOG vs VRDN Comparison
NOG vs VRDN Comparison
Compare NOG & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NOG | VRDN |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2000 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NOG | VRDN |
|---|---|---|
| Price | $25.44 | $23.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $31.14 | ★ $35.46 |
| AVG Volume (30 Days) | ★ 2.5M | 1.9M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,475,723,000.00 | $5,706,000.00 |
| Revenue This Year | $14.07 | $13.73 |
| Revenue Next Year | $4.24 | $279.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 11.23 | N/A |
| 52 Week Low | $17.18 | $13.18 |
| 52 Week High | $31.17 | $34.29 |
Technical Indicators
Market Signals| Indicator | NOG | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 71.46 | 70.86 |
| Support Level | $20.13 | $17.97 |
| Resistance Level | $25.56 | $33.71 |
| Average True Range (ATR) | 0.83 | 1.04 |
| MACD | 0.45 | 0.15 |
| Stochastic Oscillator | 91.13 | 96.87 |
Price Performance
Historical ComparisonAbout NOG Northern Oil and Gas Inc.
Northern Oil & Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. The company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), the Uinta Basin, and the Appalachian Basin (Pennsylvania and Ohio).
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.